Intravenöse Immunglobuline sind die Therapie der ersten Wahl bei der CIDP

• Literatur

• 1 van Doorn PA, Merkies IS. How to assess new drugs for neuropathies: advances in trial design and methodology. Curr Opin Neurol 2008; 21: 519-526
• 2 Hughes RA, Bouche P, Cornblath DR et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006; 13: 326-332
• 3 Cocito D, Paolasso I, Antonini G et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2010; 17: 289-294
• 4 Hughes RA, Donofrio P, Bril V et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7: 136-144
• 5 Hughes R, Bensa S, Willison H et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50: 195-201
• 6 Ropper AH. Current treatments for CIDP. Neurology 2003; 60: 16-22
• 7 Nobile-Orazio E, Cocito D, Jann S et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 2012; 11: 493-502
• 8 Buttmann M, Kaveri S, Hartung HP. Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. Trends Pharmacol Sci 2013; 34: 445-457
• 9 Lehmann HC, Hartung HP. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. Journal of neuroimmunology 2011; 231: 61-69
• 10 Rosen FS. Putative mechanisms of the effect of intravenous gamma-globulin. Clin Immunol Immunopathol 1993; 67: 41-43
• 11 Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. The Journal of clinical investigation 1994; 94: 1729-1735
• 12 Hartung HP. Advances in the understanding of the mechanism of action of IVIg. Journal of neurology 2008; 255 (Suppl. 03) 3-6
• 13 Creange A, Gregson NA, Hughes RA. Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRII expression in patients with chronic inflammatory neuropathies. J Neuroimmunol 2003; 135: 91-95
• 14 Tackenberg B, Jelcic I, Baerenwaldt A et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A 2009; 106: 4788-4792
• 15 Bick S, Tschernatsch M, Karg A et al. Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy – a new mechanism of action?. J Neuroimmunol 2013; 256: 84-90
• 16 Rodriguez M, Miller DJ, Lennon VA. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 1996; 46: 538-545
• 17 Lin CS, Krishnan AV, Park SB et al. Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2011; 68: 862-869
• 18 Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010; 9: 402-412
• 19 Gorson KC. An update on the management of chronic inflammatory demyelinating polyneuropathy. Ther Adv Neurol Disord 2012; 5: 359-373
• 20 Latov N, Deng C, Dalakas MC et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurology 2010; 67: 802-807
• 21 Eftimov F, Winer JB, Vermeulen M et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane database of systematic reviews 2009; CD001797
• 22 Hughes RA, Mehndiratta MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane database of systematic reviews 2012; (08) CD002062
• 23 Merkies IS, van Nes SI, Hanna K et al. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry 2010; 81: 1194-1199
• 24 Donofrio PD, Bril V, Dalakas MC et al. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010; 67: 1082-1088
• 25 Gorson KC. An update on the management of chronic inflammatory demyelinating polyneuropathy. Therapeutic advances in neurological disorders 2012; 5: 359-373
• 26 Hughes R. The role of IVIg in autoimmune neuropathies: the latest evidence. J Neurol 2008; 255 (Suppl. 03) 7-11
• 27 Blackhouse G, Gaebel K, Xie F et al. Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc 2010; 8: 14
• 28 Bae SC, Corzillius M, Kuntz KM et al. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 46-53